Uncovering Original Antigenic Sin By Brian Simpson

A recently published article gives some insights into the Covid vaxxed still are having numerous episodes of Covid. It seems that the vaccinated do not acquire the full spectrum of immunity of the unvaxxed through natural immunity. The simple explanation is that the vaccine in the mRNA vaccine only acquire immunity to the spike protein, which is toxic in itself. This immunity fades after a few months. However, natural immunity is more robust, and involves a more holistic immune response to the entire virus. Having more bits to go on, immunity lasts longer.

https://igorchudov.substack.com/p/moderna-knew-vaccinated-people-will?s=r

`Ever wondered why some vaccinated people seem to be having endless Covids? An interesting study came out.

This study looked at two sides of the Moderna Phase 3 vaccine trial: the vaccinated group and the control group. They looked at unvaccinated people having Covid, versus vaccinated people having so called “break-through Covid infections”.

The question that they asked, was: do the vaccinated acquire the same full-spectrum immunity as the unvaccinated?

The answer was no. Vaccinated people were much LESS likely to develop broad natural immunity, compared to unvaccinated people.

Broad Natural Immunity and Nucleocapsid Antibodies

I discuss the definition of broad spectrum immunity and explain nucleocapsid antibodies in my Nov 18 article “UK Week 42-45”. I am going to plagiarize myself and copy the text right here to make it easy for my readers:

What are these N antibodies and why am I talking about them? What’s so important?

The Covid coronavirus presents numerous “epitopes” to our immune system. Those are similar to body parts in people, those are things that the virus presents to our body just as we “present” our eyes, mouths and nose.

After defeating an infection, our immune system learns to recognize these “epitopes” and reacts later, when the pathogen is reintroduced, fighting it off easier than the first time. This is the whole point of immunity.

Skipping some details, our natural, unvaccinated immunity learns to recognize the “spikes” (S-protein), the “nucleocapsid” (N-Protein) and other pieces of the virus, and develops antibodies and immune memory reacting to all of those.

This multifaceted memory also provides broader protection against “variants”.

In contrast, vaccination with any existing Covid vaccine, floods our cells with only S-protein (the “spike protein”) from a virus that only existed around January 2020. As an aside, this spike protein is extremely toxic, it causes numerous side effects that we have heard about. Its effects depend on many things such as how exactly you were jabbed and how much of the vaccine entered the blood stream. S-protein can also penetrate cell nuclei and interfere with DNA repair.

Continuing, the point of “Covid vaccine” is that our immunity learns to recognize this S-protein and develops antibodies. This allows the vaccinated to fight off Covid-19 infection in the first few months post-vaccination. Then these S-antibodies decline, immunity wanes, and we end up with no immunity in the vaccinated.

What is important is that vaccine immunity ONLY creates antibodies for S-protein, but not for other proteins of the real virus, such as the N-protein. This is what the Roche N test is about: it detects presence of N-antibodies, which can only appear in survivors of actual Covid-19, which has N protein, which Covid vaccine lacks.

Thus, unvaccinated survivors of Covid19 develop a variety of antibodies, including S-antibodies (like the vaxxed), N-antibodies (never seen in vaxxed who did not have covid), etc.

The Moderna Trial

During the original Moderna Phase 3 trial, even before Delta and Omicron, scientists found the same effect: the vaccinated are much less likely to “seroconvert” and develop the above described N antibodies. The difference between the vaccinated and the unvaccinated is FIVE TIMES, which is huge. The unvaccinated are five times more likely than the vaccinated to develop broad immunity including N antibodies.

It gets even worse: for those vaccinated persons whose breakthrough infection occurred after the second dose, (illness detected on Day 29), their ability to develop N antibodies was 13 TIMES worse than that of the unvaccinated:

This inability to obtain broader natural immunity is the reason for endless covids: a covid infection in the vaccinated does not result in lasting immunity and acts similarly to an almost-worthless booster shot. A “breakthrough infection” adds a large number of temporary S-antibodies to the obsolete Wuhan virus. Whereas, the unvaccinated obtain numerous antibodies to all sorts of facets (epitopes) of the virus that infected them.

Authors also acknowledge importance of this finding and mention other studies showing the same effect:

N-Antibody Prevalence was Used for Questionable “Vaccine Effectiveness” Claims

It turns out that certain, perhaps intentionally misleading studies were using low N-antibody prevalence among the vaccinated, to falsely “prove” vaccine effectiveness. They would say “look how low is N antibody prevalence among the vaccinated!” as a proof that they do not get sick. But, as the above shows, it is not proof that they do not get sick! Sick or not, the vaccinees would NOT develop N antibodies.

What are those potentially misleading studies?

Implications

The implications of the failure of vaccinated people to acquire full immunity are enormous. As a result of haphazardly tested vaccines, the vaccinated cannot become naturally immune after first, second, or any further infection.

Thus, any kind of herd immunity, successfully reached by low-vaccination countries, is impossible in the highly-vaccinated countries.

Endless Covid infections are NOT harmless, because Sars-Cov-2 infects immune cells and acts as a battering ram against our immune systems. Repeated blows of this “battering ram” are extremely deleterious to the immune systems of the vaccinated.

https://www.medrxiv.org/content/10.1101/2022.04.18.22271936v1

Anti-nucleocapsid antibodies following SARS-CoV-2 infection in the blinded phase of the mRNA-1273 Covid-19 vaccine efficacy clinical trial

Dean Follmann, Holly E. Janes, Olive D. Buhule, Honghong Zhou, Bethany Girard, Kristen Marks, Karen Kotloff, Michaël Desjardins, Lawrence Corey, Kathleen M. Neuzil, Jacqueline M. Miller, Hana M. El Sahly, Lindsey R. Baden

doi: https://doi.org/10.1101/2022.04.18.22271936

Abstract

Importance The performance of immunoassays for determining past SARS-CoV-2 infection, which were developed in unvaccinated individuals, has not been assessed in vaccinated individuals.

Objective To evaluate anti-nucleocapsid antibody (anti-N Ab) seropositivity in mRNA-1273 vaccine efficacy trial participants after SARS-CoV-2 infection during the trial’s blinded phase.

Design Nested analysis in a Phase 3 randomized, placebo-controlled vaccine efficacy trial. Nasopharyngeal swabs for SARS-CoV-2 PCR testing were taken from all participants on Day 1 and Day 29 (vaccination days), and during symptom-prompted illness visits. Serum samples from Days 1, 29, 57, and the Participant Decision Visit (PDV, when participants were informed of treatment assignment, median day 149) were tested for anti-N Abs.

Setting Multicenter, randomized, double-blind, placebo-controlled trial at 99 sites in the US.

Participants Trial participants were ≥ 18 years old with no known history of SARS-CoV-2 infection and at appreciable risk of SARS-CoV-2 infection and/or high risk of severe Covid-19. Nested sub-study consists of participants with SARS-CoV-2 infection during the blinded phase of the trial.

Intervention Two mRNA-1273 (Moderna) or Placebo injections, 28 days apart.

Main Outcome and Measure Detection of serum anti-N Abs by the Elecsys (Roche) immunoassay in samples taken at the PDV from participants with SARS-CoV-2 infection during the blinded phase. The hypothesis tested was that mRNA-1273 recipients have different anti-N Ab seroconversion and/or seroreversion profiles after SARS-CoV-2 infection, compared to placebo recipients. The hypothesis was formed during data collection; all main analyses were pre-specified before being conducted.

Results We analyzed data from 1,789 participants (1,298 placebo recipients and 491 vaccine recipients) with SARS-CoV-2 infection during the blinded phase (through March 2021). Among participants with PCR-confirmed Covid-19 illness, seroconversion to anti-N Abs at a median follow up of 53 days post diagnosis occurred in 21/52 (40%) of the mRNA-1273 vaccine recipients vs. 605/648 (93%) of the placebo recipients (p < 0.001). Higher SARS-CoV-2 viral copies at diagnosis was associated with a higher likelihood of anti-N Ab seropositivity (odds ratio 1.90 per 1-log increase; 95% confidence interval 1.59, 2.28).

Conclusions and Relevance As a marker of recent infection, anti-N Abs may have lower sensitivity in mRNA-1273-vaccinated persons who become infected. Vaccination status should be considered when interpreting seroprevalence and seropositivity data based solely on anti-N Ab testing.”